Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
McKinsey
Queensland Health
Baxter
Fuji
Johnson and Johnson
Daiichi Sankyo
Cipla
Teva
Accenture

Generated: August 22, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Sertraline polymorph
Abstract:This invention relates to a novel crystalline polymorphic form of sertraline hydrochloride, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4 -tetrahydro-N-methyl-1-naphthalenamine hydrochloride, and to a method for preparing it.
Inventor(s): Sysko; Robert J. (Niantic, CT), Allen; Douglas J. M. (New London, CT)
Assignee: Pfizer Inc. (New York, NY)
Application Number:07/929,326
Patent Claims: 1. A crystalline polymorph of the hydrochloride salt of (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenam ine that exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2 .theta. at approximately 7.1, 12.7, 14.1, 15.3, 15.7, 21.2 23.4 and 26.3.

2. A crystalline polymorph of the hydrochloride salt of (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenam ine that exhibits an infrared absorption spectrum in potassium bromide having characteristic absorption bands expressed in reciprocal centimeters at approximately:

3100-3000 (W)*; 3000-2800(m)*, 2710-2500(m); 2500-2450(m); 1585(m); 1560(m); 1470-1450 (s)*; 1400(s), 1430(m); 1375(m); 1340(m) 1215(m); 1135(s); 1060(m); 1030(m); 1015(m); 955(m); 930(m); 920(m); 825(s); 800(s); 790(s); 760(s); 710(m); 700(s); 670(s); .noteq.*(w) = weak intensity; (m) = medium intensity; (s) = strong intensity.

3. A crystalline polymorph of the hydrochloride salt of (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenam ine according to claim 1 that exhibits an infrared absorption spectrum in potassium bromide having characteristic absorption bands expressed in reciprocal centimeters at approximately:

3100-3000(w)*; 3000-2800(m)*, 2710-2500(m); 2500-2450(m); 1585(m); 1560(m); 1470-1450(s)*; 1400(s), 1430(m); 1375(m); 1340(m) 1215(m); 1135(s); 1060(m); 1030(m); 1015(m); 955(m); 930(m); 920(m); 825(s); 800(s); 790(s); 760(s); 710(m); 700(s); 670(s); .noteq.*(w) = weak intensity; (m) = medium intensity; (s) = strong intensity.

4. A crystalline polymorph of the hydrochloride salt of (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenam ine that exhibits a single crystal X-ray crystallographic analysis with (a) crystal parameters that are approximately equal to the following:

wherein a, b and c and .alpha., .beta. and .gamma. are as previously defined; and (b) atomic positions of all atoms relative to the origin of the unit cell as recited in Tables 3 and 7, and as represented in FIG. 3.

5. A crystalline polymorph of the hydrochloride salt of (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl -1-naphthalenamine according to claim 1 that exhibits a single crystal X-ray crystallographic analysis with (a) crystal parameters that are approximately equal to the following:

wherein a, b and c and .alpha., .beta. and .gamma. are as previously defined; and (b) atomic positions of all atoms relative to the origin of the unit cell as recited in Tables 3 and 7, and as represented in FIG. 3.

6. A crystalline polymorph of the hydrochloride salt of (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenam ine according to claim 2 that exhibits a single crystal X-ray crystallographic analysis with (a) crystal parameters that are approximately equal to the following:

wherein a, b and c and .alpha., .beta. and .gamma. are as previously defined; and (b) atomic positions of all atoms relative to the origin of the unit cell as recited in Tables 3 and 7, and as represented in FIG. 3.

7. A crystalline polymorph of the hydrochloride salt of (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenam ine according to claim 3 that exhibits a single crystal X-ray crystallographic analysis with (a) crystal parameters that are approximately equal to the following:

wherein a, b and c and .alpha., .beta. and .gamma. are as previously defined; and (b) atomic positions of all atoms relative to the origin of the unit cell as recited in Tables 3 and 7, and as represented in FIG. 3.

8. A pharmaceutical composition comprising an amount of a polymorph according to claim 1 effective in treating depression, anxiety-related disorders, obesity, chemical dependencies or addictions orpremature ejaculation in a human, and a pharmaceutically acceptable carrier.

9. A pharmaceutical composition comprising an amount of a polymorph according to claim 2 effective in treating depression, anxiety-related disorders, obesity, chemical dependencies or addictions or premature ejaculation in a human, and a pharmaceutically acceptable carrier.

10. A pharmaceutical composition comprising an amount of a polymorph according to claim 4 effective in treating depression, anxiety-related disorders, obesity, chemical dependencies or addictions or premature ejaculation in a human, and a pharmaceutically acceptable carrier.

11. A pharmaceutical composition comprising an amount of a polymorph according to of claim 7 effective in treating depression, anxiety-related disorders, obesity, chemical dependencies or addictions or premature ejaculation in a human, and a pharmaceutically acceptable carrier.

12. A method of treating a condition selected from depression, anxiety-related disorders, obesity, chemical dependencies and addictions and premature ejaculation in a human, comprising administering to said human an amount of a polymorph according to claim 1 effective in treating such condition.

13. A method of treating a condition selected from depression, anxiety-related disorders, obesity, chemical dependencies and addictions and premature ejaculation in a human, comprising administering to said human an amount of a polymorph according to claim 2 effective in treating such condition.

14. A method of treating a condition selected from depression, anxiety-related disorders, obesity, chemical dependencies and addictions and premature ejaculation in a human, comprising administering to said human an amount of a polymorph according to claim 4 effective in treating such condition.

15. A method of treating a condition selected from depression, anxiety-related disorders, obesity, chemical dependencies and addictions and premature ejaculation in a human, comprising administering to said human an amount of a polymorph according to claim 7 effective in treating such condition.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Mallinckrodt
Novartis
Cipla
Julphar
Federal Trade Commission
Express Scripts
Chubb
Fuji
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot